A phase I/II of NF-κB Decoy for the treatment of discogenic lower back pain in the United States
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2017
At a glance
- Drugs NF kappa B Decoy-AnGes MG (Primary)
- Indications Back pain
- Focus Adverse reactions
- Sponsors AnGes MG
- 25 Apr 2017 According to an AnGes media release, the US FDA has cleared the IND application for NF-kappaB decoy oligo DNA (NF-kappaB decoy) for the treatment of discogenic lower back pain (DLBP). The company plans to initiate a phase Ib clinical trial from the middle of this year at several clinical sites including University of California San Diego.
- 24 Mar 2017 According to an AnGes media release, the company has submitted an IND application to the US FDA for initiating this trial.
- 10 Apr 2015 New trial record